ANVISA Biologics Reliance Pathway 2026: Preparing For Brazil's Reliance Framework Under RDC 741/2022 & RDC 875/2024

How ANVISA's Reliance Framework, Product Equivalence, GMP Readiness, Quality Dossiers, and Regulatory Verification Are Shaping Biologics Registration in Brazil

Brazil's ANVISA has introduced a modern reliance framework through RDC 741/2022, operational since April 2024, allowing the agency to consider regulatory assessments from recognized foreign authorities when evaluating biologic products. While this pathway can accelerate regulatory review, reliance is not automatic approval. Companies must still satisfy ANVISA's own scientific, quality, manufacturing, and regulatory requirements before products can be authorized for the Brazilian market.

Why ANVISA's Reliance Framework Matters

As biologic manufacturers expand globally, Brazil remains one of Latin America's largest and fastest growing pharmaceutical markets.

ANVISA's reliance pathway offers an opportunity to leverage approvals from trusted regulatory authorities while maintaining Brazil's independent regulatory oversight.

However, reliance should be viewed as a streamlined evaluation process not a regulatory shortcut.

Without proper preparation, organizations may encounter:

• Additional regulatory questions 
• Delayed market entry 
• Product equivalence challenges 
• Manufacturing documentation gaps 
• GMP compliance issues 
• Quality dossier deficiencies 
• Extended review timelines 
• Increased regulatory costs 

A successful reliance submission begins long before the dossier reaches ANVISA.

Executive Overview

ANVISA's reliance framework enables the agency to use foreign regulatory assessments as supporting evidence while independently assessing products for the Brazilian market.

A successful biologics submission should be:

• Regulatory complaint 
• Scientifically justified 
• Quality-driven 
• Risk-based 
• Manufacturing ready 
• Well documented 
• Inspection ready 
• Lifecycle managed 
• Supported by robust regulatory intelligence 
• Aligned with Brazilian regulatory requirements 

Organizations that proactively prepare for ANVISA-specific expectations can reduce review risks and improve submission efficiency.

Understanding ANVISA's Reliance Framework

Under RDC 741/2022, ANVISA may consider assessments performed by recognized foreign regulatory authorities as part of its own evaluation process.

However, ANVISA continues to independently evaluate:

• Product quality 
• Safety 
• Efficacy 
• Manufacturing compliance 
• Product equivalence 
• Brazilian regulatory requirements 

Foreign approvals support but do not replace ANVISA's decision-making authority.

Key Benefits of the Reliance Pathway

• More efficient regulatory review 
• Reduced duplication of regulatory assessments 
• Better use of existing scientific evidence 
• Improved regulatory consistency 
• Faster access to innovative biologics 
• More efficient lifecycle management 
• Greater predictability 
• Enhanced regulatory collaboration 

What Is ANVISA Reliance Readiness?

Reliance readiness is an organization's ability to prepare a biologics submission that fully satisfies ANVISA's scientific and regulatory expectations while leveraging eligible foreign approvals.

Core capabilities include:

• Regulatory strategy 
• Product equivalence assessment 
• Quality dossier preparation 
• GMP readiness 
• Manufacturing documentation 
• Clinical evidence review 
• Regulatory gap assessments 
• Submission planning 
• Lifecycle management 
• Regulatory intelligence 

Traditional Registration vs. Reliance Pathway

Five Key Verification Areas Before Submission

1. Regulatory Eligibility

An approval from a recognized authority (such as EMA or FDA) may make a biologic eligible for ANVISA's reliance pathway, but it does not guarantee approval in Brazil.

2. Product Equivalence

Under RDC 875/2024, companies must demonstrate product comparability and satisfy ANVISA's scientific expectations for biologics and biosimilars.

3. GMP & Manufacturing Readiness

Manufacturing sites must demonstrate compliance with ANVISA's GMP requirements, supported by complete manufacturing documentation and site readiness.

4. Quality Dossier Alignment

A dossier prepared for another regulator should be reviewed and adapted to ensure it addresses ANVISA's specific quality and technical expectations.

5. Regulatory Verification

Organizations should conduct a comprehensive readiness assessment before submission to identify documentation gaps, compliance risks, and potential review challenges.

Key Drivers of Brazil's Reliance Model

Why Product Equivalence Matters

Foreign approvals confirm that a product has met another regulator's standards, but ANVISA independently evaluates whether the product satisfies Brazilian regulatory requirements.

For biologics and biosimilars, product equivalence remains one of the most important scientific considerations during review.

1. Benefits of early equivalence assessments include:

• Improved submission quality 
• Reduced Regulatory Questions 
• Better scientific consistency 
• Lower review risks 
• Greater regulatory confidence 
• Faster market entry 

2. Building a Successful Reliance Strategy

Organizations should focus on:

• Early regulatory planning 
• Product equivalence assessments 
• ANVISA-specific dossier reviews 
• GMP readiness 
• Manufacturing documentation 
• Regulatory intelligence 
• Cross-functional collaboration 
• Submission gap assessments 

Assessing ANVISA Reliance Readiness

1. Regulatory Eligibility

Evaluation:

• Foreign approvals 
• Reliance pathway eligibility 
• Submission strategy 
• Regulatory history 
• Product scope 

2. Product Equivalence

Review:

• Comparability studies 
• Clinical evidence 
• Scientific justification 
• Reference product strategy 
• Biosimilar requirements 

3. Manufacturing & GMP

Assess:

• Manufacturing sites 
• GMP compliance 
• Quality systems 
• Site documentation 
• Supply chain readiness 

4. Quality Documentation

Evaluation:

• CTD quality module 
• Product specifications 
• Manufacturing controls 
• Stability data 
• Validation documentation 

5. Regulatory Compliance

Review:

• Brazilian requirements 
• Submission readiness 
• Documentation quality 
• Lifecycle planning 
• Regulatory intelligence 

ANVISA Reliance Readiness Assessment

Best Practices

1. Conduct Early Gap Assessments

Compare existing global dossiers against ANVISA-specific expectations.

2. Verify Product Equivalence

Confirm comparability documentation aligns with Brazilian requirements.

3. Strengthen Manufacturing Readiness

Review GMP documentation and manufacturing site compliance before submission.

4. Align Quality Dossiers

Adapt global quality documentation to ANVISA's regulatory framework.

5.Promote Cross-Functional Collaboration

Engage:

• Regulatory Affairs 
• Quality Assurance 
• Clinical Development 
• Manufacturing 
• Supply Chain 
• Medical Affairs 
• Regulatory Intelligence 
• CMC Experts 

6. Monitor Regulatory Intelligence

Stay informed about:

• RDC updates 
• ANVISA guidance 
• Reliance framework developments 
• Biologics regulations 
• International harmonization initiatives 

Common Challenges

Organizations commonly encounter:

• Assumptions about automatic approval 
• Product equivalence gaps 
• Manufacturing documentation deficiencies 
• GMP readiness issues 
• ANVISA-specific dossier differences 
• Resource constraints 
• Regulatory interpretation challenges 
• Timeline planning issues 

Common Mistakes

Avoid:

• Assuming reliance replaces regulatory review 
• Using global dossiers without localization 
• Delaying gap assessments 
• Weak manufacturing documentation 
• Limited regulatory planning 
• Insufficient equivalence justification 

ANVISA Reliance Implementation Roadmap

Future Trends

Emerging developments include:

• Expanded regulatory reliance 
• Greater international harmonization 
• Risk-based regulatory reviews 
• Digital regulatory submissions 
• Improved biologics lifecycle management 
• AI-supported regulatory evaluations 
• Enhanced GMP oversight 
• Stronger global regulatory collaboration 

Business Benefits

Frequently Asked Questions

1. What is ANVISA's reliance framework?

It allows ANVISA to use assessments from recognized foreign regulatory authorities as reference material during its own independent review of biologic products.

2. Does reliance mean automatic approval?

No. ANVISA conducts its own scientific and regulatory evaluation before granting approval.

3. Which regulations establish the framework?

RDC 741/2022 formalizes the reliance framework, while RDC 875/2024 updates requirements related to biologic product comparability and registration.

4. What is product equivalence?

It is the scientific demonstration that a biologic or biosimilar meets ANVISA's comparability expectations for the Brazilian market.

5. Is GMP documentation still required?

Yes. Manufacturing sites must demonstrate compliance with ANVISA's GMP requirements, even when products have been approved by recognized foreign authorities.

6. Why should companies perform a gap assessment?

Gap assessments help identify differences between global regulatory dossiers and ANVISA's specific requirements before submission.

7. What are the biggest challenges?

Product equivalence, manufacturing readiness, GMP documentation, quality dossier alignment, and regulatory planning.

8. How does reliance improve regulatory efficiency?

It reduces duplication of scientific assessments while preserving ANVISA's independent decision-making authority.

9. How can companies prepare?

• Conduct regulatory gap assessments 
• Verify product equivalence 
• Strengthening GMP documentation 
• Align quality dossiers 
• Monitor ANVISA regulatory updates 
• Develop a Brazil-specific submission strategy 

10. How can Maven Regulatory Solutions help?

Maven supports:

• ANVISA reliance strategy 
• Regulatory gap assessments 
• Product equivalence reviews 
• Quality dossier preparation 
• GMP documentation support 
• Regulatory intelligence 
• Submission readiness assessments 
• Lifecycle management 
• Process optimization 
• Global market access planning 

Conclusion

ANVISA's reliance framework offers biologic manufacturers a valuable opportunity to leverage trusted foreign regulatory assessments while benefiting from a more efficient review pathway. However, reliance is not a substitute for Brazilian regulatory compliance. Success depends on demonstrating product equivalence, manufacturing readiness, GMP compliance, and quality dossier alignment with ANVISA's specific expectations. Organizations that invest in early gap assessments and Brazil-focused regulatory planning will be better positioned to achieve timely approvals and successful market access.

Why Choose Maven Regulatory Solutions?

Maven Regulatory Solutions helps biologic manufacturers navigate Brazil's evolving regulatory landscape through ANVISA reliance strategy, regulatory gap assessments, product equivalence reviews, quality dossier preparation, GMP compliance support, regulatory intelligence, and submission readiness services. Our experts deliver practical, compliance-focused solutions that help organizations accelerate market access while maintaining confidence in regulatory compliance.